Screener / SEC EDGAR /CIK 0001280784 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Financials

Hercules Capital, Inc. HTGC

Compare with peers Embed
The 10-K against last year's

143 changes: 26 added, 13 removed, 101 reworded, 3 quiet changes

10-K Feb 12, 2026 vs Feb 13, 2025

10-K 0001280784-26-000009 (Feb 12, 2026) vs 10-K 0001280784-25-000007 (Feb 13, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

256 paragraphs · 23 new · 58 reworded · 10 gone · 10-K Feb 12, 2026 against Feb 13, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 137 · 48% changed Every version of it
See “Certain United States Federal Income Tax Considerations — Qualifying as a Regulated Investment Company.” Operating under these constraints may hinder our ability to take advantage of attractive investment opportunities and to achieve our investment objective. Any failure to do so could subject us to enforcement action by the SEC, cause us to fail to satisfy the tests and requirements associated with our RIC status and subject us to entity-level U.S. federal income taxation, cause us to fail the 70% test described above or otherwise have a material adverse effect on our business, financial condition or results of operations.
Paragraph 180 · 39% changed Every version of it
There is no If an active public trading market for the June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, or 2031 Asset-Backed Notes. As a result, a holder may Notes does not develop, holders could be able unable to resell any of such notes. them.
Paragraph 221 · 36% changed Every version of it
We may distribute taxable dividends that are payable in part in our stock. Under certain applicable provisions of the Code and the Treasury regulations, distributions payable by us in cash or in shares of stock (at the stockholders’ election) would satisfy the Distribution Requirements. The IRS has issued guidance providing that a dividend payable in stock or in cash at the election of the stockholders will be treated as a taxable dividend eligible for the dividends paid deduction provided that at least 20% of the total dividend is payable in cash and certain other requirements are satisfied. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such dividend is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, it may put downward pressure on the trading price of our stock.
Paragraph 212 · 32% changed Every version of it
To maintain RIC status under Subchapter M Part I of the Code, we must meet the following distribution, income and asset requirements: requirements (see “Item 1. Business — Certain United States Federal Income Tax Considerations — Qualifying as a Regulated Investment Company.”):
Paragraph 76 · 31% changed Every version of it
We value our securities for which no market value is ascertainable quarterly at fair value based on inputs from management and/or one or more third-party valuation firm(s) pursuant to our valuation guidelines approved by our Board. As of December 31, 2024, portfolio investments, whose fair value is determined in good faith by our Valuation Committee, subject to oversight and approval by our Board, were approximately 95.5% of our total assets. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of our investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. Our NAV could be adversely affected if determinations regarding the fair value of these investments were materially higher than the values ultimately realized upon the disposal of such investments.
Paragraph 235 · 30% changed Every version of it
There The U.S. government has indicated its intent, made proposals and taken actions to alter its approach to international trade policy and in some cases to renegotiate, or potentially terminate, existing bilateral or multi-lateral trade agreements and treaties with foreign countries. Some foreign governments, including China, have been ongoing discussion and commentary regarding potential significant changes to instituted retaliatory tariffs on certain U.S. trade policies, treaties and tariffs, creating significant uncertainty about the future relationship between the United States and other countries with respect to trade policies, treaties and tariffs. goods. These developments, or the perception that more of them could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global trade and, in particular, trade between the impacted nations and the United States. Any of these factors could depress economic activity and restrict our portfolio companies’ access to suppliers or customers and have a material adverse effect on their business, financial condition and results of operations, which in turn would negatively impact us.
Paragraph 44 · 30% changed Every version of it
Pharmaceutical companies are also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Pharmaceutical companies may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of pharmaceutical companies to comply with applicable laws and regulations can result in the imposition of civil and criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such as Medicare and Medicaid. Pharmaceutical companies may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize current and any future products depends in part on the extent to which reimbursement for the cost of such products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of medical products. Significant uncertainty exists as to the reimbursement status of health care products, and there can be no assurance that adequate third-party coverage will be available for pharmaceutical companies to obtain satisfactory price levels for their products.
Paragraph 200 · 29% changed Every version of it
The agreements governing the June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes and January 2027 June 2030 Notes require us to offer to prepay all of the issued and outstanding notes upon a change in control and election by the holders, which could have a material adverse effect on our business, financial condition and results of operations. A change in control under the indentures or note purchase agreements, as applicable, occurs upon the consummation of a transaction which results in a “person” or “group” (as those terms are used in the Exchange Act and the rules promulgated thereunder) becoming the beneficial owner of more than 50% of our outstanding voting stock.

MD&A

140 paragraphs · 3 new · 51 reworded · 3 gone · 10-K Feb 12, 2026 against Feb 13, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 96 · 43% changed
During the year ended December 31, 2023, 2025, we recognized a net realized gain loss of $8.4 $40.8 million. The net realized gains (losses) were generated from gross realized gains of approximately $29.9 $32.1 million primarily from the sale of our equity and warrant positions in Palantir Technologies, Provention Bio, Axsome Therapeutics, Inc., TransMedics Group, BridgeBio Pharma, Inc and Madrigal Pharmaceuticals, Inc. and collections from our equity and warrants related to Akero Therapeutics, Inc., Sprinklr, Inc., DoorDash, Inc., Couchbase, Inc. and Zeta Global Corp. Next Insurance, Inc. following capital market transactions or events. Our gross realized gains were offset by gross realized losses of $21.5 $70.6 million from the write-off of equity and warrant investments in Concert Pharmaceuticals, Inc. and Fungible, Inc., which had no value after the respective portfolio companies were acquired, as well as the write-off of our equity investments in Gynesonics, Inc. Paratek Pharmaceuticals, Inc., Tricida, Inc., Gelesis, Inc. and Flowonix Medical Inc. as a result of capital market transactions or events. Additionally, we realized a net $6.3 million loss from the write-off of our debt investments relating to Codiak Biosciences, Inc. restructure of Khoros, LLC and Esme Learning Solutions, Annex Cloud and sale of AmplifyBio, LLC and Carbon Health Technologies, Inc., which are net and the write-off of recovered collections our equity and warrant investments in HilleVax, Inc., Chrome Holding Co. (p.k.a 23andMe, Inc.), bluebird bio, Inc., and others. Additionally, we recognized a foreign exchange loss of $17.5 million. $2.1 million related to investments in foreign denominated debt investments and a forward contract.
Paragraph 97 · 40% changed
During the year ended December 31, 2024, we recognized a net realized loss of $31.7 million. The net realized losses were generated from a realized loss of $63.1 million from the write-off of our debt investments relating to Convoy, Inc., Gritstone Bio, Inc., Better Therapeutics, Inc., and Eigen Technologies Ltd., which are net of recovered collections of $55.5 million. $44.6 million of the write-off of our debt investments resulted in a reversal of unrealized depreciation previously reported as of December 31, 2023. We also realized a loss of $7.1 million primarily from the write-off of equity and warrant investments in Sio Gene Therapies, Inc., Eigen Technologies Ltd., Humanigen, Inc., Proterra, Inc., and Fulcrum Bioenergy, Inc. The net realized losses were partially offset by gross realized gains of $39.7 million primarily from the sale
Paragraph 127 · 37% changed
As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the macro-economic events, potential global recession, acts of terrorism, war, geopolitical events, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.
Paragraph 91 · 37% changed
Employee stock-based compensation totaled approximately $14.6 million for the year ended December 31, 2025, as compared to approximately $12.8 million for the year ended December 31, 2024, as compared to approximately $13.2 million 2024. The increase for the year ended December 31, 2023. The decrease for the year ended December 31, 2024 2025 was primarily attributable to a decrease an increase in compensation expense related to Performance the grant date fair value of the Service Vesting Awards (as defined below) which vested in 2023. “Note 8 — Equity Incentive Plans — Service Vesting Awards” to our consolidated financial statements).
Paragraph 125 · 36% changed
The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. On August 15, 2024, we obtained We do not currently have the authorization from our stockholders to issue common stock at a price below our then-current NAV per share for a twelve-month period expiring on August 15, 2025. For a further discussion, refer to Part I, Item 1A “Risk Factors- Risks Related to our Securities - Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then-current NAV per share of and there is no guarantee that we will obtain such authorization from our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock” appearing elsewhere stockholders in this Annual Report. the future.
Paragraph 114 · 33% changed
(in thousands) millions) Year Ended December 31, 2025 2024 2023 Recurring interest Dividend income $ 441,361 8.2 $ 410,414 Non-recurring interest 6.8 Expenses allocated 15.2 10.8 Interest income 17,934 22,611 Dividend income 7,900 1,400 Total interest and dividend income $ 467,195 $ 434,425 — 0.6
Paragraph 85 · 30% changed
The decrease in fee income for the year ended December 31, 2024 was similar 2025, as compared to the year ended December 31, 2023. This 2024, is primarily due to higher weighted average principal outstanding lower prepayment penalty from early repayments and fee income from lower fees recognized on expired commitments, partially offset by lower acceleration of higher recurring fee income from early repayments. an increase in the weighted average principal outstanding.
Paragraph 120 · 27% changed
During the year ended December 31, 2024, 2025, our financing activities provided $119.2 $368.9 million of cash, compared to $22.7 $119.2 million provided during the year ended December 31, 2023. 2024. The $96.5 $249.7 million increase in cash flows from financing activities during the year ended December 31, 2024 2025 was primarily due to an increase in net borrowings borrowing activity of $236.9 $289.2 million, partially offset by a $119.9 decrease of $13.9 million decrease in equity issued and a $29.8 million increase in dividend distributions. During the year ended December 31, 2024, we issued. We distributed dividends of $303.5 $326.0 million compared to $273.7 million during the year ended December 31, 2023. We also reduced the usage of our overnight offering and ATM program, which provided (net of offering costs) approximately $218.3 million down from $338.2 $303.5 million, during the years ended December 31, 2024 2025 and 2023. 2024, respectively. During the year ended December 31, 2025, our ATM program provided (net of offering costs) approximately $204.4 million compared to $218.3 million net proceeds received during the year ended December 31, 2024. During the year ended December 31, 2025, we issued $287.5 million in aggregate principal amount of 2028 Convertible Notes and $350.0 million in aggregate principal amount of June 2030 Notes. Additionally, during the year ended December 31, 2025, we fully repaid the aggregate outstanding $50.0 million, $70.0 million, and $50.0 million principal of the February 2025 Notes, June 2025 Notes, and June 2025 3-Year Notes, respectively.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Legal Proceedings324 words changed in this paragraph; it is 33% similar to last year's version.
(in thousands) Unfunded Commitments (1) as of Portfolio Company December 31, 2024 2025 December 31, 2023 AlphaSense, 2024 DNSFilter, Inc. $ 4,000 5,000 $ — Saama Technologies, Smartsheet Inc. 4,840 — PayIt, LLC 3,875 3,875 Allvue Systems, LLC 3,590 3,590 LogRhythm, 4,800 8,000 Babel Street 3,275 4,367 Loftware, Inc. 3,143 2,846 2,277 Funnel Holding AB (publ) 2,625 — Zappi, Inc. 2,571 2,571 Loftware, Octave Health Group, Inc. 2,277 2,277 Streamline Healthcare Solutions 2,200 2,200 2,500 — Tidal Vision Products, Inc. 2,500 — Carbyne, Inc. 2,334 — Proven Optics, LLC 2,250 — New Relic, Inc. 2,176 2,176 Streamline Healthcare Solutions 2,100 2,200 Behavox Limited 2,100 — Sumo Logic, Inc. 2,000 2,000 Ceros, Inc. 1,707 1,707 Akeyless Security Ltd. 2,000 — Saama Technologies, LLC 1,938 3,875 LogicSource 1,209 1,209 TaxCalc 1,166 Zimperium, Inc. 1,087 196 Alchemer LLC 890 — Dispatch Technologies, Inc. 625 563 LinenMaster, LLC 338 1,000 1,000 ShadowDragon, LLC 333 333 TaxCalc 311 1,166 Omeda Holdings, LLC 160 731 Thumbtack, Inc. — 30,000 Armis, Inc. — 25,000 Coronet Cyber Security Ltd. — 17,000 Locus Robotics Corp. — 16,250 Akero Therapeutics, Inc. — 15,000 Dragos, Inc. — 13,000 Aryaka Networks, Inc. — 12,500 WellBe Senior Medical, LLC — 12,000 Strive Health Holdings, LLC — 8,299 Suzy, Inc. — 8,000 Heron Therapeutics, Inc. — 8,000 ATAI Life Sciences N.V. — 7,000 Dashlane, Inc. — 5,000 AlphaSense, Inc. — 4,000 Allvue Systems, LLC — 3,590 LogRhythm, Inc. — 3,143 Ceros, Inc. — 1,707 3GTMS, LLC — 886 1,182 Main Street Rural, Inc. — 874 10,500 Fortified Health Security — 840 840 Omeda Holdings, LLC 731 731 Flight Schedule Pro, LLC — 646 639 DroneDeploy, Inc. 625 6,250 Dispatch Technologies, Inc. 563 625 ShadowDragon, LLC 333 333 Zimperium, Inc. 196 3,727 Automation Anywhere, Inc. — 29,400 Checkr Group, Inc. — 23,625 Skydio, Inc. — 22,500 Tarsus Pharmaceuticals, Inc. — 20,625 Kura Oncology, Inc. — 19,250 Tipalti Solutions Ltd. — 10,500 Next Insurance, Inc. — 10,000 Senseonics Holdings, Inc. — 8,750 Elation Health, Inc. — 7,500 Modern Life, Inc. — 6,500 Phathom Pharmaceuticals, Inc. — 6,120 Brain Corporation — 5,000 Leapwork ApS — 3,900 Riviera Partners LLC — 3,000 Cutover, Inc. — 2,650 Plentific Ltd — 2,625 Altumint, Inc. — 2,500 Yipit, LLC — 2,250 Annex Cloud — 1,750 ThreatConnect, Inc. — 1,600 Ikon Science Limited — 1,050 Agilence, Inc. — 800 Constructor.io Corporation — 625 Enmark Systems, Inc. — 457 Alchemer LLC — 445 Cybermaxx Intermediate Holdings, Inc. — 390 Cytracom Holdings LLC — 72 Total Unfunded Debt Commitments: 382,234 444,699 330,828

Source: Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001280784-26-000009 vs Item 3, via Note 11 – Commitments and Contingencies, 10-K 0001280784-25-000007

Risk Factors196 words changed in this paragraph; it is 50% similar to last year's version.
We may distribute taxable dividends that are payable in part in our stock. Under certain applicable provisions of the Code and the Treasury regulations, distributions payable by us in cash or in shares of stock (at the stockholders’ election) would satisfy the Distribution Requirements. The IRS has issued guidance providing that a dividend payable in stock or in cash at the election of the stockholders will be treated as a taxable dividend eligible for the dividends paid deduction provided that at least 20% of the total dividend is payable in cash and certain other requirements are satisfied. Taxable stockholders receiving such dividends will be required to include the full amount of the dividend as ordinary income (or as long-term capital gain to the extent such dividend is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such dividends in excess of any cash received. If a U.S. stockholder sells the stock it receives as a dividend in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the dividend, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such dividends, including in respect of all or a portion of such dividend that is payable in stock. In addition, if a significant number of our stockholders determine to sell shares of our stock in order to pay taxes owed on dividends, it may put downward pressure on the trading price of our stock.

Source: Item 1A, 10-K 0001280784-26-000009 vs Item 1A, 10-K 0001280784-25-000007

MD&A184 words changed in this paragraph; it is 42% similar to last year's version.
During the year ended December 31, 2023, 2025, we recognized a net realized gain loss of $8.4 $40.8 million. The net realized gains (losses) were generated from gross realized gains of approximately $29.9 $32.1 million primarily from the sale of our equity and warrant positions in Palantir Technologies, Provention Bio, Axsome Therapeutics, Inc., TransMedics Group, BridgeBio Pharma, Inc and Madrigal Pharmaceuticals, Inc. and collections from our equity and warrants related to Akero Therapeutics, Inc., Sprinklr, Inc., DoorDash, Inc., Couchbase, Inc. and Zeta Global Corp. Next Insurance, Inc. following capital market transactions or events. Our gross realized gains were offset by gross realized losses of $21.5 $70.6 million from the write-off of equity and warrant investments in Concert Pharmaceuticals, Inc. and Fungible, Inc., which had no value after the respective portfolio companies were acquired, as well as the write-off of our equity investments in Gynesonics, Inc. Paratek Pharmaceuticals, Inc., Tricida, Inc., Gelesis, Inc. and Flowonix Medical Inc. as a result of capital market transactions or events. Additionally, we realized a net $6.3 million loss from the write-off of our debt investments relating to Codiak Biosciences, Inc. restructure of Khoros, LLC and Esme Learning Solutions, Annex Cloud and sale of AmplifyBio, LLC and Carbon Health Technologies, Inc., which are net and the write-off of recovered collections our equity and warrant investments in HilleVax, Inc., Chrome Holding Co. (p.k.a 23andMe, Inc.), bluebird bio, Inc., and others. Additionally, we recognized a foreign exchange loss of $17.5 million. $2.1 million related to investments in foreign denominated debt investments and a forward contract.

Source: Item 7, 10-K 0001280784-26-000009 vs Item 7, 10-K 0001280784-25-000007

Accounting Policies99 words changed in this paragraph; it is 41% similar to last year's version.
Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001280784-26-000009 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001280784-25-000007

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of HTGC's Risk Factors and MD&A, 10-K Feb 12, 2026 against 10-K Feb 13, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Any investment in a portfolio company carries the risk that the portfolio company will make a material misrepresentation or omission in connection with the investment. Such inaccuracy or incompleteness could adversely affect, among other things, the valuation of collateral underlying loans or other debt obligations, our ability to perfect or effectuate a lien on the collateral securing a loan or other debt obligation, the financial condition of the portfolio company or the business prospects of the portfolio company. We, as well as subsidiaries through which we may obtain indirect leveraged exposure to the underlying obligors or portfolio companies of underlying loans, will rely upon the accuracy and completeness of representations made by the underlying obligors or portfolio companies to the extent reasonable. However, there can be no guarantee that these representations are accurate or complete.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedRisk Factors
In periods of declining interest rates, our interest income and our net investment income could be reduced as the interest income earned on our floating rate debt investments declines and any new fixed rate debt may be issued at lower coupon rates. Additionally, in periods of declining interest rates, the rate of prepayments has historically tended to increase (as does price fluctuation) as borrowers are motivated to pay off debt and refinance at new lower rates. During such periods, we would expect reinvestment of the prepayment proceeds by us to generally be at lower rates of return than the return on the assets that were prepaid.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedRisk Factors
We consolidate the financial statements of Hercules Funding IV LLC (“Hercules Funding IV”), our special purpose wholly owned subsidiary that is the borrower under the MUFG Bank Facility, in our consolidated financial statements and treat the indebtedness of such subsidiary as our leverage. Our interests in any wholly owned direct or indirect subsidiary of ours would be subordinated in priority of payment to every other obligation of any such subsidiary and would be subject to certain payment restrictions set forth in any credit facility, including the MUFG Bank Facility. We would receive cash distributions on our equity interests in any such subsidiary only if such subsidiary had made all required cash interest payments to the lenders and no default exists under any credit facility. We cannot assure you that distributions on the assets held by any such subsidiary would be sufficient to make any distributions to us or that such distributions would meet our expectations.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedRisk Factors
We would receive cash from any such subsidiary only to the extent that we would receive distributions on our equity interests in such subsidiary. Any such subsidiary would be able to make distributions on its equity interests only to the extent permitted by the payment priority provisions of the relevant credit facility. We expect that any credit facility would generally provide that payments on such interests may not be made on any payment date unless all amounts owing to the lenders and other secured parties are paid in full. In addition, if such subsidiary would not meet the borrowing base test set forth in any credit facility documents, a default would occur. In the event of a default under any credit facility documents, cash would be diverted from us to pay the lender and other secured parties until they would be paid in full. In the event that we would fail to receive cash from such subsidiary, we could be unable to make distributions to our stockholders in amounts sufficient to maintain our status as a RIC, or at all. We also could be forced to sell investments in portfolio companies at less than their fair value in order to continue making such distributions.
Read it in 10-K Feb 12, 2026 at sec.gov
Show the other 47
AddedRisk Factors
Our equity interests in any such subsidiary would rank behind all of the secured and unsecured creditors, known or unknown, of such subsidiary, including the lenders in any credit facility. Consequently, to the extent that the value of such subsidiary’s portfolio of loan investments would have been reduced as a result of conditions in the credit markets, defaulted loans, capital gains and losses on the underlying assets, prepayment or changes in interest rates, the return on our investment in such subsidiary could be reduced. Accordingly, our investment in such subsidiary may be subject to up to a complete loss.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedRisk Factors
The MUFG Bank Facility places significant restrictions on our ability, as servicer, to sell investments, and we expect that any credit facility we enter into in the future would include similar restrictions. As a result, there may be times or circumstances during which we would be unable to sell investments or take other actions that might be in our best interests.
Read it in 10-K Feb 12, 2026 at sec.gov
RemovedRisk Factors
Development” industry,16.7% comprised investments in the “Healthcare Services, Other” industry, and 10.2% in the “Consumer & Business Services industry”. Companies in technology-related industries are subject to numerous risks, including:
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
•Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options.
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
common stock, the percentage ownership of our stockholders at that time would decrease, and they may experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on favorable terms or at all.
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
The issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our common stock by making an investment in the common stock less attractive. In addition, the dividends on any preferred stock we issue must be cumulative. Payment of dividends and repayment of the liquidation preference of preferred stock must take preference over any dividends or other payments to our common stockholders, and holders of preferred stock are not subject to any of our expenses or losses and are not entitled to participate in any income or appreciation in excess of their stated preference (other than convertible preferred stock that converts into common stock). In addition, under the 1940 Act, preferred stock constitutes a “senior security” for purposes of the asset coverage test.
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
The agreements governing our indebtedness, including our Notes and Credit Facilities, require us to comply with certain financial, operational and payment covenants. These covenants require us to, among other things, maintain certain financial ratios, including asset coverage, debt to equity and interest coverage. Our ability to continue to comply with these covenants in the future depends on many factors, some of which are beyond our control. Any default under such
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
There is significant uncertainty with respect to legislation, regulation and government policy at the federal level, as well as the state and local levels. Recent events, including the 2024 U.S. presidential election, have created a climate of heightened uncertainty and introduced new and difficult-to-quantify macroeconomic and political risks with potentially far-
Read it in 10-K Feb 13, 2025 at sec.gov
RemovedRisk Factors
reaching implications. To the extent the U.S. Congress or the presidential administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business, financial condition, operating results and cash flows. Until we know what policy changes are made and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.
Read it in 10-K Feb 13, 2025 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, approximately 85.9% 87.1% of the fair value of our portfolio comprised investments in four five industries: 29.5% 24.3% comprised investments in the “Software” industry , 29.5% "Application Software" industry, 23.3% comprised investments in the “Drug "Drug Discovery & Development" industry,18.8% comprised investments in the "Healthcare Services, Other" industry, 10.6% in the "System Software" industry, and 10.1% comprised investments in the "Consumer & Business Services" industry.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
In addition, the current U.S. political environment and the new incoming U.S. federal administration and the resulting uncertainties regarding actual and potential shifts in U.S. foreign investment, trade, healthcare, taxation, economic, environmental and other policies, as well as the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the U.S. and China or the conflict between Russia and Ukraine or conflict in the Middle East, could lead to disruption, instability and volatility in the global capital markets.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
(in thousands) December 31, 2024 2025 Fair Value Percentage of Net Assets Phathom Pharmaceuticals, Inc. $ 177,348 8.9% 182,883 8.3% Marathon Health, LLC 166,882 8.4% Axsome Therapeutics, 181,337 8.2% Armis, Inc. 165,220 8.3% 159,672 7.2% ChenMed, LLC 128,240 5.8% Shield AI, Inc. 113,701 5.7% 118,127 5.3% Tipalti Solutions Ltd. 113,467 5.1% SeatGeek, Inc. 110,413 5.5% Corium, Inc. 109,178 5.5% 111,031 5.0%
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
There currently is no active public trading market for the June 2025 Notes, June 2025 3-Year Notes, The March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, or 2031 Asset-Backed Notes. Notes may or may not have an active trading market.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
There is no If an active public trading market for the June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, or 2031 Asset-Backed Notes. Notes does not develop, holders could be unable to resell them.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
Annual Return on Our Portfolio (Net of Expenses) -10% -5% (10%) (5%) 0% 5% 10% Corresponding return to common stockholder assuming our actual asset coverage of 231.7% 212.1% as of December 31, 2024(1) (23.77%) (14.14%) (4.51%) 5.12% 14.75% 2025(1) (25.94%) (15.59%) (5.25%) 5.09% 15.44% Corresponding return to common stockholder assuming 150% asset coverage(2) (42.32%) (26.52%) (10.72%) 5.08% 20.89% (42.46%) (26.62%) (10.78%) 5.06% 20.90%
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
However, as an internally managed BDC, our ability to offer more competitive and flexible compensation structures, structures is subject to the limitations imposed by the 1940 Act, such as limitations on offering both a profit-sharing plan and an equity incentive plan, is subject to the limitations imposed by the 1940 Act, which limits may limit our ability to attract and retain talented investment management professionals.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
In addition, under the terms of any credit facility or other debt instrument we enter into, in the event of a default, we are likely to be required by its terms to use the net proceeds of any investments that we sell to repay a portion of the amount borrowed under such facility or instrument before applying such net proceeds to any other uses.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
Lenders of these senior securities will have fixed dollar claims on our assets that are superior to the claims of our common stockholders, and we would expect such lenders to seek recovery against our assets in the event of a default.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
We could experience fluctuations in our operating results due to a number of factors, including our ability or inability to make investments in companies that meet our investment criteria, the interest rate payable on the debt securities we acquire, the level of portfolio dividend and fee income, the level of our expenses, variations in and the timing of the recognition of realized and unrealized gains or losses, the degree to which we encounter competition in our markets and general economic conditions.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
Our secured credit facilities with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”) and MUFG Union Bank, N.A., Ltd., (the “MUFG Bank Facility”) and our letter of credit facility with Sumitomo Mitsui Banking Corporation (the “SMBC LC Facility” and together with the SMBC Facility and MUFG Bank Facility, our “Credit Facilities”), as well as the February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, June 2030 Notes, 2031 Asset-Backed Notes and 2033 Notes (each term as is individually defined under “Note 5 - Debt” and collectively, the “Notes”), each outstanding as of December 31, 2024, 2025, contain financial and operating covenants that could restrict our business activities, including our ability to declare dividend distributions if we default under certain provisions.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedRisk Factors
Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the 2033 Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes and January 2027 June 2030 Notes may have important consequences for their holders, including making it more difficult for us to satisfy our obligations with respect to the 2033 Notes, September 2026 Notes, January 2027 Notes, 2028 Convertible Notes and January 2027 June 2030 Notes or negatively affecting their trading value.
Read it in 10-K Feb 12, 2026 at sec.gov
Quiet changesRisk Factors
We may seek puts or similar rights to give us the right to sell our equity securities back to the portfolio company issuer; however, we may not be unable able to exercise these put rights for the consideration provided in our investment documents if the issuer is in financial distress.
Read it in 10-K Feb 12, 2026 at sec.gov
Quiet changesRisk Factors
Because certain of our senior securities have customary cross-default and cross-acceleration provisions, if the indebtedness under our senior securities is accelerated, we may not be unable able to repay or finance the amounts due.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedMD&A
(1)Effective December 31, 2025, the former “Software” category has been separated into “Application Software” and “System Software”. Prior year amounts have been reclassified to conform to the current presentation.
Read it in 10-K Feb 12, 2026 at sec.gov
AddedMD&A
within the reporting period; and (ii) $96.2 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.gov
RemovedMD&A
(in millions) December 31, 2024 December 31, 2023 Beginning Portfolio $ 3,248.0 $ 2,963.9 New fundings and restructures 1,807.2 1,598.6 Fundings assigned to or directly funded by the Adviser Funds (383.2) (350.7) Warrants not related to current period fundings 0.3 1.3 Principal repayments received on investments (31.6) (50.8) Early payoffs (922.0) (925.1) Proceeds from sale of debt investments — (26.7) Proceeds from sale of equity and warrant investments (49.4) (43.2) Accretion of loan discounts and paid-in-kind interest 87.7 59.5 Net acceleration of loan discounts and loan fees due to early payoffs or restructures (12.3) (14.1) New loan fees (15.2) (13.5) Gain (loss) on investments due to sales or write offs (19.7) 6.0 Net change in unrealized appreciation (depreciation) (49.8) 42.8 Ending Portfolio $ 3,660.0 $ 3,248.0
Read it in 10-K Feb 13, 2025 at sec.gov
RewordedMD&A
(in thousands) Year Ended December 31, 2025 2024 2023 Debt Equity, Warrants Total Debt Equity, Warrants Total and and Investment Funds(1) Funds(2) Investment Funds(1) Funds(2) Investment valuation appreciation (depreciation) $ (5,049) $ 14,891 $ 9,842 $ (45,718) $ (6,162) $ (51,880) $ 26,689 $ 26,401 $ 53,090 Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event(2) event(1) 28,755 (4,301) 24,454 26,665 (23,655) 3,010 (6,556) (5,373) (11,929) Other net changes in unrealized appreciation (depreciation) (depreciation)(2) 12,697 (8,181) 4,516 (816) 18,477 17,661 (15,612) (539) (16,151) Net change in unrealized appreciation (depreciation) $ 36,403 $ 2,409 $ 38,812 $ (19,869) $ (11,340) $ (31,209) $ 4,521 $ 20,489 $ 25,010
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
The net realized losses were generated from a realized loss of $63.1 million from the write-off of our debt investments relating to Convoy, Inc., Gritstone Bio, Inc., Better Therapeutics, Inc., and Eigen Technologies Ltd., which are net of recovered collections of $55.5 million. $44.6 million of the write-off of our debt investments resulted in a reversal of unrealized depreciation previously reported as of December 31, 2023.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
(in The following table shows the amortized cost of our performing and non-accrual investments as of December 31, 2025 and December 31, 2024:(in millions) As of December 31, 2025 2024 2023 Amortized Cost Percentage of Total Portfolio at Amortized Cost Amortized Cost Percentage of Total Portfolio at Amortized Cost Performing $ 4,457 99.8% $ 3,648 98.3% $ 3,216 99.0% Non-accrual 11 0.2% 61 1.7% 31 1.0% Total Investments $ 4,468 100.0% $ 3,709 100.0% $ 3,247 100.0%
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
(in A summary of net realized gains and losses for the years ended December 31, 2025 and 2024 is as follows:(in thousands) Year Ended December 31, 2025 2024 2023 Realized gains $ 32,096 $ 39,676 $ 29,920 Realized losses (70,553) (70,175) (21,493) Realized foreign exchange gains (losses) (2,154) (987) 10 Realized loss on debt extinguishment of debt (184) (171) — Net realized gains (losses) $ (40,795) $ (31,657) $ 8,437
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
During We distributed dividends of $326.0 million compared to $303.5 million, during the year years ended December 31, 2025 and 2024, we distributed dividends of $303.5 million compared to $273.7 million during the year ended December 31, 2023. respectively.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
We also reduced During the usage of year ended December 31, 2025, our overnight offering and ATM program, which program provided (net of offering costs) approximately $204.4 million compared to $218.3 million down from $338.2 million, net proceeds received during the years year ended December 31, 2024 and 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
Employee stock-based compensation totaled approximately $14.6 million for the year ended December 31, 2025, as compared to approximately $12.8 million for the year ended December 31, 2024, as compared to approximately $13.2 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $139.7 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
(2)Included in (1)For the years ended December 31, 2025 and 2024, reversals of prior period net changes in unrealized appreciation (depreciation) are include $45.2 million and $44.6 million million, respectively, of reversed unrealized depreciation, related to the $57.7 million and $63.1 million million, respectively, of realized debt loss losses from the write-off of certain debt investments noted above.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
(2)Included in (1)For the years ended December 31, 2025 and 2024, reversals of prior period net changes in unrealized appreciation (depreciation) are include $45.2 million and $44.6 million million, respectively, of reversed unrealized depreciation, related to the $57.7 million and $63.1 million million, respectively, of realized debt loss losses from the write-off of certain debt investments noted above.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
As of December 31, 2024, 2025, we had $658.8 $525.5 million in available liquidity, including $113.1 $57.0 million in cash, cash equivalents and foreign cash, and available borrowing capacity of approximately $16.2 $21.5 million (net of $0.5 million of outstanding letter of credits) under the SMBC Facility, $175.0 million under our SMBC letter of credit facility, $284.0 and $272.0 million under the MUFG Bank Facility, and $71.0 million of SBA debentures, subject to certain conditions.
Read it in 10-K Feb 12, 2026 at sec.gov
RewordedMD&A
The increase in expenses allocated to the Adviser Subsidiary for the year ended December 31, 2024 2025 compared to 2023 2024 is due to higher average assets under management an increase in time spent on the Adviser Funds and higher allocations an increase in investments allocated to the Adviser Funds.
Read it in 10-K Feb 12, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HTGC/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.